Foghorn Therapeutics (FHTX) Q1 2025 Earnings
Foghorn Therapeutics reported Q1 2025 revenue of $6.0M (+17.9% YoY), missed analyst consensus of $6.2M by $287.7K. Diluted EPS came in at $-0.30 (+49.2% YoY).
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Foghorn Therapeutics's Q1 2025 earnings report.
Foghorn Therapeutics (FHTX) reported Q1 2025 earnings on May 14, 2025 before market open.
Foghorn Therapeutics reported revenue of $6.0M and diluted EPS of $-0.30 for Q1 2025.
Revenue missed the consensus estimate of $6.2M by $287.7K. EPS beat the consensus estimate of $-0.30 by $0.00.
Compared to the same quarter a year prior, revenue grew 17.9% from $5.1M a year earlier and diluted EPS grew 49.2% from $-0.59.
You can read the 10-Q periodic report (0001628280-25-025312) directly on SEC EDGAR. The filing index links above go to sec.gov.